Alembic Pharmaceuticals Q2 net profit rises 62% to Rs 2.07 billion

Vadodara-based pharma major Alembic Pharmaceuticals posted a 69 per cent year-on-year (YoY) jump in net profit for the second quarter of this fiscal year to Rs 2.07 billion, riding on a one-time supply opportunity of valsartan products to the US. 

The revenues grew 43 per cent to Rs 11.27 billion. 

The company's international revenues posted robust growth of 124 per cent for the quarter under review to Rs 5.87 billion.

Pranav Amin, managing director at Alembic Pharmaceuticals, said: "A one-time supply opportunity arising due to a product shortage in the US market has resulted in higher profits." If the valsartan